Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant in Major Depressive Disorder
NCT02476058Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoint: Adverse Events. Started Jun 2015; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02476058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476058.